REMICADE Antitrust Settlement Receives Final Approval
LexBlog IP
APRIL 12, 2023
In 2017, three indirect-purchaser antitrust class actions were filed against Johnson & Johnson and Janssen Biotech, Inc., alleging that they engaged in anticompetitive conduct relating to the sale and marketing of J&J’s REMICADE (infliximab). The court preliminarily approved the settlement in August 2022.
Let's personalize your content